ALKERMES | ALKS - Ricavi Di Vendita





I Saldi Cambiamento Data
AbbVie USD 17.4B 410M 2026-09
Acadia Pharmaceuticals USD 342M 34.04M 2026-09
ALKERMES USD 480.13M 15.88M 2026-09
Amgen USD 10.4B 300M 2026-09
Biogen USD 2.8B 60M 2026-09
BioMarin Pharmaceutical USD 1.03B 40M 2026-09
Bristol-Myers Squibb USD 13.07B 100M 2026-09
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 24.4B 1.43B 2026-09
Gilead Sciences USD 8.3B 500M 2026-09
Heron Therapeutics USD 40.59M 2.38M 2025-12
Ionis Pharmaceuticals USD 243M 25M 2026-09
J&J USD 25.4B 89M 2026-09
Merck USD 18.1B 1.5B 2026-09
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 10.86M 10.95M 2026-03
Neurocrine Biosciences USD 1.12B 161M 2026-09
Otsuka Holdings JPY 710.05B 8B 2026-09
Pfizer USD 16.6B 1.57B 2026-09
Regeneron Pharmaceuticals USD 5.12B 830M 2026-09
Vertex Pharmaceuticals USD 3.44B 110M 2026-09